Literature DB >> 1480733

Effect of anticholinergics on positive and negative symptoms in schizophrenia.

R Tandon1, J R DeQuardo, J Goodson, N A Mann, J F Greden.   

Abstract

Anticholinergic drugs have been assumed to have no effects on schizophrenic symptomatology. Some studies suggest, however, that anticholinergic agents may antagonize the beneficial effect of neuroleptics on positive symptoms and partially ameliorate negative symptoms. Virtually all studies have been conducted in patients receiving concomitant neuroleptic treatment, raising the possibility that neuroleptics may obscure or modify any "true" anticholinergic effect on schizophrenic symptoms. To evaluate the hypothesis that anticholinergics may increase positive and decrease negative schizophrenic symptoms, we assessed the effect of biperiden on symptoms in the medication-free state. We studied the effect of biperiden 8 mg/day for 2 days on positive and negative symptoms in 40 otherwise drug-free schizophrenic inpatients. Biperiden produced a significant increase in positive symptoms (t = 6.7, p < .001) and reduction in negative symptoms (t = -3.4, p < .01). These data indicate that cholinergic modulation significantly affects positive and negative schizophrenic symptoms and suggest the need for systematic trials of cholinergic and anticholinergic agents in the treatment of positive and negative symptoms of schizophrenia, respectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1480733

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  10 in total

1.  Cholinergic modulation of auditory processing, sensory gating and novelty detection in human participants.

Authors:  Inge Klinkenberg; Arjan Blokland; Wim J Riedel; Anke Sambeth
Journal:  Psychopharmacology (Berl)       Date:  2012-10-03       Impact factor: 4.530

2.  Effects of anticholinergic challenge on psychopathology and cognition in drug-free patients with schizophrenia and healthy volunteers.

Authors:  Tanja Veselinović; Ingo Vernaleken; Hildegard Janouschek; Thilo Kellermann; Michael Paulzen; Paul Cumming; Gerhard Gründer
Journal:  Psychopharmacology (Berl)       Date:  2014-11-07       Impact factor: 4.530

3.  Varenicline for cognitive impairment in people with schizophrenia: systematic review and meta-analysis.

Authors:  Timothy Tanzer; Shelukumar Shah; Catherine Benson; Veronica De Monte; Victoria Gore-Jones; Susan L Rossell; Frances Dark; Steve Kisely; Dan Siskind; Catarina Drumonde Melo
Journal:  Psychopharmacology (Berl)       Date:  2019-12-03       Impact factor: 4.530

Review 4.  New drug developments in psychosis: Challenges, opportunities and strategies.

Authors:  Matcheri S Keshavan; Ashley N Lawler; Henry A Nasrallah; Rajiv Tandon
Journal:  Prog Neurobiol       Date:  2016-08-09       Impact factor: 11.685

Review 5.  Cholinergic circuits and signaling in the pathophysiology of schizophrenia.

Authors:  Joshua A Berman; David A Talmage; Lorna W Role
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

6.  Blockade of muscarinic acetylcholine receptors facilitates motivated behaviour and rescues a model of antipsychotic-induced amotivation.

Authors:  Jonathan M Hailwood; Christopher J Heath; Benjamin U Phillips; Trevor W Robbins; Lisa M Saksida; Timothy J Bussey
Journal:  Neuropsychopharmacology       Date:  2018-11-27       Impact factor: 7.853

Review 7.  Targeting muscarinic receptors to treat schizophrenia.

Authors:  Daniel J Foster; Zoey K Bryant; P Jeffrey Conn
Journal:  Behav Brain Res       Date:  2021-02-26       Impact factor: 3.332

8.  REM sleep latency and neurocognitive dysfunction in schizophrenia.

Authors:  Mrinmay Das; Ruchika Das; Udayan Khastgir; Utpal Goswami
Journal:  Indian J Psychiatry       Date:  2005-07       Impact factor: 1.759

Review 9.  New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis.

Authors:  Albert C Yang; Shih-Jen Tsai
Journal:  Int J Mol Sci       Date:  2017-08-03       Impact factor: 5.923

10.  Microstructural imaging and transcriptomics of the basal forebrain in first-episode psychosis.

Authors:  Min Tae M Park; Peter Jeon; Leon French; Kara Dempster; M Mallar Chakravarty; Michael MacKinley; Julie Richard; Ali R Khan; Jean Théberge; Lena Palaniyappan
Journal:  Transl Psychiatry       Date:  2022-09-01       Impact factor: 7.989

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.